Arcutis Biotherapeutics, Inc.
ARQT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001787306
In the last 90 days, Arcutis Biotherapeutics, Inc. insiders filed 0 open-market purchases and 12 sales; 272 institutions reported holding it in 13F filings for Q2 2026, worth $3.45B in total; no superinvestor holds it.
13F holders, Q1 2022
Institutional positions in Arcutis Biotherapeutics, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 106
- +14 vs. Q4 2021
- Shares held
- 48.3M
- +1.99M (+4.3%) vs. Q4 2021
- Total value
- $929.8M
- −$31.0M (−3.2%) vs. Q4 2021
- New holders
- 22
- 31 more added
- Sold out
- 8
- 29 more reduced
1 institution that held it in Q4 2021 haven't filed for Q1 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ARQT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 272 | $3.45B |
| Q1 2026 | 270 | $3.12B |
| Q4 2025 | 283 | $3.75B |
| Q3 2025 | 239 | $2.37B |
| Q2 2025 | 230 | $1.78B |
| Q1 2025 | 241 | $1.97B |
| Q4 2024 | 208 | $1.79B |
| Q3 2024 | 188 | $1.20B |
| Q2 2024 | 186 | $1.18B |
| Q1 2024 | 168 | $1.24B |
| Q4 2023 | 133 | $327.1M |
| Q3 2023 | 134 | $356.7M |
| Q2 2023 | 136 | $684.0M |
| Q1 2023 | 144 | $787.6M |
| Q4 2022 | 141 | $979.6M |
| Q3 2022 | 139 | $1.13B |
| Q2 2022 | 115 | $1.05B |
| Q1 2022 | 106 | $929.8M |
| Q4 2021 | 93 | $961.8M |
| Q3 2021 | 103 | $1.09B |
| Q2 2021 | 102 | $1.24B |
| Q1 2021 | 94 | $1.35B |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Arcutis Biotherapeutics, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Polar Capital Holdings Plc | 1,784,005 | $34.4M | 0.20% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $76.6M | 7.44% | 00.0% | Unchanged |
| BlackRock Inc. | 4,315,802 | $83.1M | 0.00% | +1,9380.0% | Added |
| OrbiMed Advisors LLC | 6,073,850 | $117.0M | 1.90% | 00.0% | Unchanged |
| FMR LLC | 7,557,593 | $145.6M | 0.01% | +13,381+0.2% | Added |
| Frazier Life Sciences Management, L.P. | 8,434,232 | $162.4M | 13.84% | +8,434,232 | New |
| Frazier Management LLC | 0 | $0 | 0.00% | −8,434,232−100.0% | Sold out |
| TD Asset Management Inc | 0 | $0 | 0.00% | −35,920−100.0% | Sold out |
| Martingale Asset Management L P | 0 | $0 | 0.00% | −23,111−100.0% | Sold out |
| IndexIQ Advisors LLC | 0 | $0 | 0.00% | −14,598−100.0% | Sold out |
| SG Americas Securities, LLC | 0 | $0 | 0.00% | −8,251−100.0% | Sold out |
| Migdal Insurance & Financial Holdings Ltd. | 0 | $0 | 0.00% | −263−100.0% | Sold out |
| CWM, LLC | 0 | $0 | 0.00% | −22−100.0% | Sold out |
| Covestor Ltd | 0 | $0 | 0.00% | −16−100.0% | Sold out |
| AlphaCentric Advisors LLC | – | – | – | – | Not filed |